HOWL
Werewolf Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
0.83
▲ 0.40 (91.79%)
MARKET · —
Price
Open
0.75
Prev close
0.43
Day high
1.05
Day low
0.86
Volume
290.43M
Market cap
$42.45M
P/E (TTM)
—
52W range
0.27 – 2.38
Trailing performance
Returnvs SPY
1W
+115.80%
+117.2%
1M
+142.78%
+139.0%
3M
+107.11%
+104.0%
6M
+30.45%
+19.4%
YTD
+37.85%
+25.6%
1Y
-29.52%
-49.5%
3Y
-66.89%
-141.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$42.45M
Enterprise value$20.46M
Revenue (TTM)$21.00M
Gross profit$-5.18M
EBITDA$-21.92M
Net income$-34.61M
EPS (TTM)$-0.73
Free cash flow$-12.23M
Total cash$21.99M
Total debt$0
Book value / share$0.34
Shares outstanding48.60M
Float47.92M
Short % of float2.74%
Dividend yield—
Beta (5Y)0.29
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.48
PEG ratio—
Price / sales—
Price / book2.61
EV / revenue0.97
EV / EBITDA-0.93
Gross margin-24.69%
Operating margin40.65%
Profit margin-164.82%
Return on equity-119.86%
Return on assets-27.39%
Debt / equity—
Current ratio2.91
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $0 | $1.89M | $19.94M | $16.40M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$60.82M | -$70.52M | -$37.37M | -$53.81M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$60.82M | -$70.52M | -$37.37M | -$53.81M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.32 | 0.14 | +145.2% |
| Mar 2026 | -0.30 | -0.28 | +5.1% |
| Dec 2025 | -0.35 | -0.17 | +51.0% |
| Sep 2025 | -0.38 | -0.36 | +5.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.32 | 1 | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | -1.27 | 1 | $0 | 0.0% |
| Next year | -1.60 | 2 | $0 | 0.0% |
Analyst targets & ownership
Mean target$7.00
High target$7.00
Low target$7.00
Implied upside746.43%
Analyst count1
ConsensusNONE
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders1.40%
Held by institutions29.09%
Institutions holding58
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
682.33K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 7, 26 | EVNIN LUKE BASIL Director |
SELL | 143.20K | $44.75K | Indirect |
| Jun 29, 26 | EVNIN LUKE BASIL Director |
SELL | 157.08K | $47.13K | Indirect |
| Jun 17, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 416.91K | $145.92K | Indirect |
| Jun 16, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 448.84K | $173.76K | Indirect |
| Jun 11, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 678.23K | $253.57K | Indirect |
| Jun 9, 26 | EVNIN LUKE BASIL Director |
SELL | 76.93K | $28.46K | Indirect |
| Jun 8, 26 | EVNIN LUKE BASIL Director |
SELL | 105.56K | $43.03K | Indirect |
| Jun 3, 26 | EVNIN LUKE BASIL Director |
SELL | 139.80K | $63.63K | Indirect |
| May 29, 26 | EVNIN LUKE BASIL Director |
SELL | 141.11K | $66.20K | Indirect |
| May 26, 26 | EVNIN LUKE BASIL Director |
SELL | 191.76K | $86.56K | Indirect |
| May 20, 26 | EVNIN LUKE BASIL Director |
SELL | 171.05K | $76.36K | Indirect |
| May 13, 26 | EVNIN LUKE BASIL Director |
SELL | 44.68K | $24.13K | Indirect |
| May 12, 26 | EVNIN LUKE BASIL Director |
SELL | 407.57K | $280.21K | Indirect |
| May 12, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 565.17K | $390.69K | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
EVNIN LUKE BASIL |
Director | — | Sale |
GADICKE ANSBERT S. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
MPM BIOVENTURES 2014,L.P. |
Unknown | — | Sale |
RA CAPITAL MANAGEMENT, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
Moving averages & technicals
SMA 10
0.45
+85.09% from price
SMA 20
0.43
+101.66% from price
SMA 50
0.39
+124.53% from price
SMA 100
0.53
+54.82% from price
SMA 200
0.66
+32.79% from price
EMA 12
0.48
+73.31% from price
EMA 26
0.44
+90.09% from price
EMA 50
0.44
+89.43% from price
RSI (14)
86.1
Overbought
MACD (12,26,9)
0.04
Hist 0.03
ATR (14)
0.07
8.18% of price
Realised vol 30D
242.4%
Annualised
Bollinger upper
0.65
20, 2σ
Bollinger lower
0.22
20, 2σ
50 / 200 cross
Death
0.39 vs 0.66
Trend bias
Above 200
+32.79%
Risk profile
Beta vs SPY
2.12
More volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
242.4%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-85.9%
Peak to trough
Max drawdown 5Y
-98.4%
Peak to trough
ATR 14
0.07
8.18% of price
Beta (reported)
0.29
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.05
Call-heavy session
Put / call open interest
0.55
Positioning, not flow
Max pain
2.50
+186.2% from spot
ATM implied vol
243.8%
Nearest strike to spot
Skew (10% OTM)
-3.1%
Calls bid over puts
Call volume
876
Contracts, this expiry
Put volume
42
Contracts, this expiry
Heaviest call OI
2.50
255 contracts
Heaviest put OI
5.00
72 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Little-Known HOWL Stock Skyrockets 100% on Biotech Merger News
Barchart · 22h ago
Sector Update: Healthcare Stocks Advance in Afternoon Trading
MT Newswires · 23h ago
BC-Most Active Stocks
Associated Press · 1d ago
Werewolf Therapeutics shares surge 120% after Ambros merger and $150 million financing
InvestorsHub · 1d ago
Sector Update: Healthcare Stocks Edge Higher Pre-Bell Friday
MT Newswires · 1d ago
Werewolf Therapeutics to Merge With Ambros Therapeutics in All-Stock Deal
MT Newswires · 1d ago
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement
GlobeNewswire · 1d ago
Top Premarket Gainers
MT Newswires · 1d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.